morrhuate sodium (Rx)

Brand and Other Names:Scleromate
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 50mg/mL

Obliteration of Varicose Veins

May use test dose of 0.25-1 mL of 5% solution

Small/medium Veins: 50-100 mg IV

Large Veins: 150-250 mg IV

May repeat q5-7Days

Safety & efficacy not established

Next:

Adverse Effects

Frequency Not Defined

Drowsiness

Headache

Burning or cramping sensations

Pulmonary embolism

Anaphylactic reactions

Injection site reactions

Previous
Next:

Warnings

Contraindications

Hypersensitivity to product or components

Persistent deep vein occlusion

Valvular or deep vein incompetence

Acute superficial thrombophlebitis; underlying arterial disease

Varicosities caused by abdominal & pelvic tumors

Uncontrolled DM, thyrotoxicosis, TB, neoplasms, asthma, sepsis, blood dyscrasias, acute respiratory or skin disease

Bedridden patients continuing administration following a systemic reaction or unusual local reaction at the injection site

Extensive therapy in patients that are senile or severely debilitated

Cautions

Delay therapy in patients with acute local or systemic infections

Extensive therapy inadvisable in severely debilitated/senile patients

Extravasation may cause tissue necrosis

Burning and cramping sensations reported following administration

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Not studied

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Sclerosing agent, causes inflammation of vascular intima layer and subsequently thrombus formation, which in turn forms fibrous tissue and thrombus formation that obliterates the vein

Previous
Next:

Administration

IV Administration

May use a test dose (0.25-1 mL) first to determine sensitivity

If solid matter present, warm ampule by immersing in hot water until clear

Because injection froths easily, a large bore needle should be used to fill syringe

Use smaller bore needle for injection

May give dose as single or multiple injections

Storage

Store at 15-30°C

Do not expose to air

Do not freeze

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.